biomy, Inc. provides innovative services for pharmaceutical companies using AI and biological technologies. We develop an AI platform that maximizes medication efficacy by selecting the appropriate cohort through unsupervised AI analysis of past patient information. Conventional medication criteria in companion diagnostics have been determined by reducing information from the vast amount of information inherent in test results to "expression levels of specific proteins" or "genetic mutations in the genome". We can predict the prognosis of anti-tumor drugs by picking up various information in the test results using AI, and to support decision making on medication.